<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635984</url>
  </required_header>
  <id_info>
    <org_study_id>818888</org_study_id>
    <nct_id>NCT02635984</nct_id>
  </id_info>
  <brief_title>Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens</brief_title>
  <acronym>FOND-O</acronym>
  <official_title>Randomized, Placebo Controlled Study of FOND (Fosaprepitant, Ondansetron, Dexamethasone) Versus FOND+O (FOND Plus Olanzapine) for the Prevention of Chemotherapy Induced Nausea and Vomiting in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Georgia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the effectiveness of olanzapine added to standard
      triplet therapy (fosaprepitant, ondansetron, and dexamethasone) versus triplet therapy alone
      in preventing chemotherapy-induced nausea and vomiting (CINV) in hematology patients
      receiving highly or moderately emetogenic chemotherapy regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nausea and vomiting remains a common and difficult to manage consequence of chemotherapy
      despite prophylaxis. These symptoms can often lead to a decreased quality of life,
      dehydration, and malnutrition. Olanzapine is an atypical antipsychotic that blocks multiple
      neuronal receptors involved in nausea/vomiting pathways. Olanzapine has been studied for
      breakthrough chemo-induced nausea and vomiting (CINV) as well as in prophylaxis of highly and
      moderately emetogenic regimens (HEC and MEC, respectively). However, these studies have
      focused on patients with solid tumor malignancies and chemotherapy regimens of short
      duration. To date, no publications have reported outcomes from adding olanzapine to standard
      triplet therapy, for hematology patients, including those undergoing hematopoietic stem cell
      transplants and those who receive multi-day HEC and MEC regimens.

      This is a blinded, placebo controlled trial randomizing patients to receive olanzapine 10 mg
      orally on all chemotherapy days plus three additional days post chemotherapy or placebo in
      addition to standard triplet therapy (ondansetron and dexamethasone on each day of
      chemotherapy and fosaprepitant 150 mg IV on day one of chemotherapy). Inclusion criteria: age
      18 or older, receiving inpatient or outpatient HEC or MEC chemotherapy including those
      regimens given before stem cell transplantation (ABVD, ICE ± R, 7+3 or 5+2, BEAM, Bu/Cy ±
      ATG, Bu/Flu ± ATG, FluCy ± ATG, BuMel, FluBuCy, Melphalan). Exclusion criteria: allergy to
      olanzapine, documented nausea/vomiting ≤24 hours before enrollment, treatment with other
      antipsychotic agents, or declined informed consent. Patients will be randomized to placebo or
      olanzapine in a block design stratified by chemotherapy type (transplant conditioning vs.
      chemotherapy only) and number of days of chemotherapy (single vs. multi-day) by the
      Investigational Drug Pharmacy services at Augusta University Medical Center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Percentage of Patients Who Had a Complete Response</measure>
    <time_frame>Until study completion; estimated 1.5 years</time_frame>
    <description>Overall percentage of patients who had a complete response (CR) defined as no emesis and minimal nausea (&lt; 25 mm on a 100 mm visual analog scale [VAS]) during the overall assessment period (starting day 1 of chemotherapy and continuing for 5 days after discontinuation of chemotherapy) for the first cycle of chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With no Significant Nausea in Overall Assessment Period</measure>
    <time_frame>Until study completion; estimated 1.5 years</time_frame>
    <description>Reported for overall phases [chemotherapy days plus 5 days after] where all VAS &lt; 25 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Achieving Complete Protection in Overall Assessment Phase</measure>
    <time_frame>Until study completion; estimated 1.5 years</time_frame>
    <description>(CP = no emesis, no breakthrough antiemetic use, no significant nausea). To be reported as overall phases [chemotherapy days plus 5 days after]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With no Significant Nausea in Acute Phase</measure>
    <time_frame>Until study completion; estimated 1.5 years</time_frame>
    <description>Reported as acute [chemotherapy days]. All assessment with all VAS &lt; 25 mm on days of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With no Significant Nausea in Delayed Phase</measure>
    <time_frame>Until study completion; estimated 1.5 years</time_frame>
    <description>Reported for delayed [5 days after chemotherapy administration] All assessment with all VAS &lt; 25 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With no Nausea in Overall Assessment Period</measure>
    <time_frame>Until study completion; estimated 1.5 years</time_frame>
    <description>No nausea (all VAS &lt;5 mm) in overall assessment period (days of chemotherapy plus five days after)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With Complete Response in Acute Phase</measure>
    <time_frame>Until study completion; estimated 1.5 years</time_frame>
    <description>Complete response (no emesis and no more than minimal nausea, defined as &lt; 25 mm on a 100 mm visual analog scale [VAS]) in acute phase (days of chemotherapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With Complete Response in Delayed Phase</measure>
    <time_frame>Until study completion; estimated 1.5 years</time_frame>
    <description>Complete response (no emesis and no more than minimal nausea, defined as &lt; 25 mm on a 100 mm visual analog scale [VAS]) in delayed phase (5 days after chemotherapy)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Complications of Bone Marrow Transplant</condition>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Triplet Therapy Plus Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triplet Therapy Plus Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy</description>
    <arm_group_label>Triplet Therapy Plus Olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy</description>
    <arm_group_label>Triplet Therapy Plus Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatient or outpatient hematology patient receiving one of the following regimens:

          -  Chemotherapy for hematologic malignancy:

          -  ABVD

          -  ICE ± R

          -  7+3

          -  Conditioning therapy for stem cell transplantation:

          -  BEAM

          -  Bu/Cy ± ATG

          -  Bu/Flu ± ATG

          -  FluCy ± ATG

          -  FluCy + TBI

          -  BuMel

          -  FluBuCy

          -  Melphalan

          -  Etoposide + TBI

          -  Cyclophosphamide + TBI

        Exclusion Criteria:

          -  Allergy to olanzapine

          -  Documented nausea or vomiting ≤24 hours prior to enrollment

          -  Treatment with other antipsychotic agents such as risperidone, quetiapine, clozapine,
             phenothiazine or butyrophenone ≤30 days prior to enrollment or planned during protocol
             therapy

          -  Chronic alcoholism

          -  Pregnant

          -  Declined or unable to provide an informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amber B Clemmons, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <results_first_submitted>June 22, 2018</results_first_submitted>
  <results_first_submitted_qc>July 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2018</results_first_posted>
  <last_update_submitted>July 18, 2018</last_update_submitted>
  <last_update_submitted_qc>July 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Amber Clemmons</investigator_full_name>
    <investigator_title>Pharmacist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02635984/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Triplet Therapy Plus Placebo</title>
          <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
Placebo: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy</description>
        </group>
        <group group_id="P2">
          <title>Triplet Therapy Plus Olanzapine</title>
          <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
Olanzapine: Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Arm Closed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Triplet Therapy Plus Placebo</title>
          <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
Placebo: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy</description>
        </group>
        <group group_id="B2">
          <title>Triplet Therapy Plus Olanzapine</title>
          <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
Olanzapine: Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="22" upper_limit="74"/>
                    <measurement group_id="B2" value="54" lower_limit="22" upper_limit="72"/>
                    <measurement group_id="B3" value="55" lower_limit="22" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment Regimen</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Chemotherapy Alone</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HCT Conditioning</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Percentage of Patients Who Had a Complete Response</title>
        <description>Overall percentage of patients who had a complete response (CR) defined as no emesis and minimal nausea (&lt; 25 mm on a 100 mm visual analog scale [VAS]) during the overall assessment period (starting day 1 of chemotherapy and continuing for 5 days after discontinuation of chemotherapy) for the first cycle of chemotherapy.</description>
        <time_frame>Until study completion; estimated 1.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triplet Therapy Plus Placebo</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
Placebo: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Triplet Therapy Plus Olanzapine</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
Olanzapine: Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Percentage of Patients Who Had a Complete Response</title>
          <description>Overall percentage of patients who had a complete response (CR) defined as no emesis and minimal nausea (&lt; 25 mm on a 100 mm visual analog scale [VAS]) during the overall assessment period (starting day 1 of chemotherapy and continuing for 5 days after discontinuation of chemotherapy) for the first cycle of chemotherapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on an 80 % power and an alpha of 0.05, we estimated a need for 49 patients in each treatment arm. From a review of existing literature, the sample size was based on an estimated CR achieved in 65 % of patients on triplet therapy alone and a hypothesized clinically relevant increase of 25 % for the treatment group to 90 %.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With no Significant Nausea in Overall Assessment Period</title>
        <description>Reported for overall phases [chemotherapy days plus 5 days after] where all VAS &lt; 25 mm</description>
        <time_frame>Until study completion; estimated 1.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triplet Therapy Plus Placebo</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
Placebo: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Triplet Therapy Plus Olanzapine</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
Olanzapine: Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With no Significant Nausea in Overall Assessment Period</title>
          <description>Reported for overall phases [chemotherapy days plus 5 days after] where all VAS &lt; 25 mm</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients Achieving Complete Protection in Overall Assessment Phase</title>
        <description>(CP = no emesis, no breakthrough antiemetic use, no significant nausea). To be reported as overall phases [chemotherapy days plus 5 days after]</description>
        <time_frame>Until study completion; estimated 1.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triplet Therapy Plus Placebo</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
Placebo: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Triplet Therapy Plus Olanzapine</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
Olanzapine: Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Achieving Complete Protection in Overall Assessment Phase</title>
          <description>(CP = no emesis, no breakthrough antiemetic use, no significant nausea). To be reported as overall phases [chemotherapy days plus 5 days after]</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With no Significant Nausea in Acute Phase</title>
        <description>Reported as acute [chemotherapy days]. All assessment with all VAS &lt; 25 mm on days of chemotherapy</description>
        <time_frame>Until study completion; estimated 1.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triplet Therapy Plus Placebo</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
Placebo: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Triplet Therapy Plus Olanzapine</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
Olanzapine: Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With no Significant Nausea in Acute Phase</title>
          <description>Reported as acute [chemotherapy days]. All assessment with all VAS &lt; 25 mm on days of chemotherapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With no Significant Nausea in Delayed Phase</title>
        <description>Reported for delayed [5 days after chemotherapy administration] All assessment with all VAS &lt; 25 mm</description>
        <time_frame>Until study completion; estimated 1.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triplet Therapy Plus Placebo</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
Placebo: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Triplet Therapy Plus Olanzapine</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
Olanzapine: Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With no Significant Nausea in Delayed Phase</title>
          <description>Reported for delayed [5 days after chemotherapy administration] All assessment with all VAS &lt; 25 mm</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With no Nausea in Overall Assessment Period</title>
        <description>No nausea (all VAS &lt;5 mm) in overall assessment period (days of chemotherapy plus five days after)</description>
        <time_frame>Until study completion; estimated 1.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triplet Therapy Plus Placebo</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
Placebo: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Triplet Therapy Plus Olanzapine</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
Olanzapine: Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With no Nausea in Overall Assessment Period</title>
          <description>No nausea (all VAS &lt;5 mm) in overall assessment period (days of chemotherapy plus five days after)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With Complete Response in Acute Phase</title>
        <description>Complete response (no emesis and no more than minimal nausea, defined as &lt; 25 mm on a 100 mm visual analog scale [VAS]) in acute phase (days of chemotherapy)</description>
        <time_frame>Until study completion; estimated 1.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triplet Therapy Plus Placebo</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
Placebo: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Triplet Therapy Plus Olanzapine</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
Olanzapine: Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With Complete Response in Acute Phase</title>
          <description>Complete response (no emesis and no more than minimal nausea, defined as &lt; 25 mm on a 100 mm visual analog scale [VAS]) in acute phase (days of chemotherapy)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With Complete Response in Delayed Phase</title>
        <description>Complete response (no emesis and no more than minimal nausea, defined as &lt; 25 mm on a 100 mm visual analog scale [VAS]) in delayed phase (5 days after chemotherapy)</description>
        <time_frame>Until study completion; estimated 1.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triplet Therapy Plus Placebo</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
Placebo: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Triplet Therapy Plus Olanzapine</title>
            <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
Olanzapine: Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With Complete Response in Delayed Phase</title>
          <description>Complete response (no emesis and no more than minimal nausea, defined as &lt; 25 mm on a 100 mm visual analog scale [VAS]) in delayed phase (5 days after chemotherapy)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality, serious, and other (non-serious) adverse events were not monitored/assessed during this study. Adverse events were reported only via quantification of number of subjects who withdrew from study for potential adverse events (by patient report or investigator discretion). The time frame in which withdrawal from study was monitored for each patient was the duration of active study period (chemotherapy plus five days after).</time_frame>
      <desc>All-cause mortality, serious, and other (non-serious) adverse events were not monitored/assessed.
Adverse events were monitored only by quantifying number of subjects who withdrew from study for potential adverse events (by patient report or investigator discretion).</desc>
      <group_list>
        <group group_id="E1">
          <title>Triplet Therapy Plus Placebo</title>
          <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
Placebo: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy</description>
        </group>
        <group group_id="E2">
          <title>Triplet Therapy Plus Olanzapine</title>
          <description>All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
Olanzapine: Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Withdrawal From Study</sub_title>
                <description>Patient or physician request to withdrawal from study</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Amber Clemmons, Clinical Pharmacist - BMT/Hematology &amp; Clinical Associate Professor</name_or_title>
      <organization>AU Medical Center / University of Georgia College of Pharmacy</organization>
      <phone>706-721-6493</phone>
      <email>aclemmons@augusta.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

